Independent Medical Education Grants
Takeda Pharmaceuticals IME Grants fund independent, evidence-based education to advance clinical knowledge in oncology, gastroenterology, hematology, immunology, neuroscience, rare metabolic diseases, and transplant care.
Funder: Takeda Pharmaceuticals
Due Dates (Anticipated): June 2026
Funding Amounts: Typical award size and duration not specified; funding varies by project and scope.
Summary: Supports independent, evidence-based medical education to advance clinical knowledge and improve patient care in oncology and related fields.
Description
Takeda Pharmaceuticals offers Independent Medical Education (IME) Grants to support high-quality, unbiased, evidence-based educational initiatives for healthcare professionals, teams, patients, payers, and health systems. The program aims to close clinical and practice gaps, enhance clinical knowledge and skills, and empower patients to actively participate in their healthcare. Supported activities must be planned and implemented independently of industry influence and be fair-balanced and scientifically rigorous.
Areas of interest include, but are not limited to:
- Oncology: Colorectal cancer, chronic phase chronic myeloid leukemia, lymphoma, Philadelphia chromosome-positive acute lymphoblastic leukemia, polycythemia vera, and ALK-positive non-small cell lung cancer
- Gastroenterology: Inflammatory bowel disease, eosinophilic esophagitis, short bowel syndrome-intestinal failure
- Hematology: Von Willebrand disease, hemophilia A
- Immunology: Chronic inflammatory demyelinating polyradiculoneuropathy, hereditary angioedema, primary immunodeficiency disease
- Neuroscience: Narcolepsy type 1
- Rare metabolic diseases: Gaucher disease, Hunter syndrome
- Transplant: Cytomegalovirus infection
Certain topics and disease areas are not eligible for funding; see the "Eligibility" section below for details.
